Bender, Jeffrey R.
- Targetsite Therapeutics Corporation (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #37,005
- Sustained Excellence
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2001 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$245K
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#37,005
By linked amount among FY2023 PIs
Earliest Year Loaded
2001
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Bender, Jeffrey R. as a PI. Multi-PI records show the full award amount for context.
- 1R43HL170910-01R43Contact PIIL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)$245Kaward amount
Award organization
Organizations that administered FY2023 awards listing Bender, Jeffrey R. as a PI.
FY2023 award administered by Targetsite Therapeutics Corporation ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2001First NIH AwardTargetsite Therapeutics Corporation
- 2001$500K Cumulative Funding
- 2001Entered Top 50% NationallyRanked #3463
- 2001Entered Top 25% NationallyRanked #3463
- 2002$1M Cumulative Funding
- 2002$2M Cumulative Funding
- 2005$5M Cumulative Funding